Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abdominal Aortic Aneurysm
Studies conducted at Osaka University on abdominal aortic aneurysm recently published
March 9th, 2008
"Because current therapy to treat abdominal aortic aneurysm (AAA), and particularly to manage small AAA, is limited to elective surgical repair, we explored less invasive molecular therapy by simultaneous inhibition of the transcription factors nuclear factor (NF)kappa B and ets using a decoy strategy. Both NF kappa B and ets were shown to be markedly activated in human AAA," scientists writing in the journal Circulation Research report. "In addition, NF kappa B- and ets- positive cells were increased in the aneurysm wall, and a part of the expression of NF kappa B and ets was detected in migrating macrophages. Thus, we used chimeric decoy oligodeoxynucleotides...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-09)
|
